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Myc is a transcription factor which is dependent on its DNA binding domain for transcriptional regulation
of target genes. Here, we report the surprising finding that Myc mutants devoid of direct DNA binding activity
and Myc target gene regulation can rescue a substantial fraction of the growth defect in myc/ fibroblasts.
Expression of the Myc transactivation domain alone induces a transcription-independent elevation of the RNA
polymerase II (Pol II) C-terminal domain (CTD) kinases cyclin-dependent kinase 7 (CDK7) and CDK9 and a
global increase in CTD phosphorylation. The Myc transactivation domain binds to the transcription initiation
sites of these promoters and stimulates TFIIH binding in an MBII-dependent manner. Expression of the Myc
transactivation domain increases CDK mRNA cap methylation, polysome loading, and the rate of translation.
We find that some traditional Myc transcriptional target genes are also regulated by this Myc-driven trans-
lation mechanism. We propose that Myc transactivation domain-driven RNA Pol II CTD phosphorylation has
broad effects on both transcription and mRNA metabolism.
Members of the Myc family are champion oncogenes (12,
45). N-Myc or c-Myc expression is frequently elevated in can-
cers of diverse origins, and transgenic mice with elevated Myc
expression develop tumors in many organs. In normal cellular
physiology, Myc induction is an integrator of extracellular sig-
nals which drive cell proliferation. Growth factors induce Myc
expression, and this induction is necessary for cell proliferation
(4, 19). During oncogenesis, Myc expression becomes elevated
independently of growth factors and survival signals, permit-
ting unrestrained cell proliferation.
Myc forms a heterodimer with Max and operates as a tran-
scription factor which both activates and represses genes. Nu-
merous microarray analyses have revealed that Myc is a weak
but pleiotropic transcription factor, activating or repressing
around 5 to 10% of all genes about 1.5- to 2-fold (16). A
number of Myc cofactors facilitate this role. Myc binds to the
TRRAP complex, recruiting histone acetylation activity to pro-
moters, which promotes transcription by opening up chromatin
structure (34, 35). Myc has also been found to bind and act in
conjunction with other transcriptional regulators (15). In ad-
dition to driving transactivation, Myc has also been found to
drive transcription elongation via the recruitment of P-TEFb
(positive transcription elongation factor b) (18). Full Myc tran-
scriptional activity is associated with rapid turnover of the
protein, and Skp2, HectH9, and Fbw7 mediate this process (1,
24, 56–58). Regardless of the cofactor involved, transactivation
ultimately must increase RNA polymerase II (Pol II) activity,
but exactly how Myc does this remains unclear.
Myc/Max was first characterized as a sequence-specific tran-
scription factor that binds to a consensus site, CACGTG (6).
This sequence has been validated as the binding site required
for stimulated transactivation of many target genes (http://www
.myc-cancer-gene.org). However, the necessity for Myc to
function by binding to the Myc consensus sequence has been
called into question by in vivo Myc binding studies which have
placed Myc at promoters without consensus binding sites (10,
20, 26, 30, 44). Currently, it remains unclear whether Myc
functions at all of these nonconsensus sites and indeed whether
there is always a consequence to Myc binding near a promoter.
Myc has not been found to regulate transcription at many of
the promoters it binds to, but the possibility remains that Myc
has some transcription-independent role at these sites.
RNA polymerase II activity is governed by a cycle of phosphor-
ylation and dephosphorylation of the large subunit C-terminal
domain (CTD) (5, 29, 52). Hypophosphorylated RNA Pol II is
recruited to initiation complexes, and transcription initiation is
associated with TFIIH-driven CTD serine-5 (S5) phosphorylation
(42). After 20 to 50 nucleotides have been transcribed, RNA
becomes capped by the addition of an inverted 7-methyl-
guanosine triphosphate in a series of reactions which are most
efficient when cotranscriptional (13, 46). Capping requires three
sequential enzymatic activities. RNA triphosphatase removes the
terminal phosphate from the first nucleotide, and guanylyltrans-
ferase adds an inverted guanylyl to the mRNA. In mammals, both
of these enzymes are present in the same polypeptide, which is
recruited and activated by the S5-P CTD (11, 33, 55, 59). The
third step is 7-methylation of the guanosine, and the methyltrans-
ferase is also recruited by the S5-P CTD (25, 48). Guanosine
addition stabilizes the mRNA against degradation, but the
mRNA becomes competent to be translated only when methyl-
ated (50, 51). Since the capping enzymes are recruited and acti-
vated by the phosphorylated CTD, transcription and mRNA pro-
cessing are intricately linked and codependent.
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We initiated a study of Myc biological activity that is inde-
pendent of direct DNA binding and transcriptional activation
or repression. We present the striking finding that Myc can
promote a global elevation in phosphorylation of the RNA Pol
II CTD which has a potentially broad impact on transcription,
mRNA processing, and translation.
MATERIALS AND METHODS
Cell culture, transfection, retroviral infection, siRNA transfection, and assays.
Rat-1fibroblasts (TGR cells), rat c-myc null fibroblasts (HO15.19 cells), Tet-21/N
cells, and retroviral producer PhoeNX cells were cultured in Dulbecco modified
Eagle medium-10% fetal calf serum. Immortalized mammary epithelial cells
(IMECs) were cultured as previously described (17). Retroviral infection of
HO15.19 and IMECs was performed using PhoeNX cells. Tet-21/N cells were
maintained in 0.2 g/ml doxycycline for 2 days to repress N-myc expression. For
growth curves, 104 cells from log-phase cultures were plated in six-well plates.
Every 24 h, cells were trypsinized and counted using a hemocytometer. Cells
expressing cyclin-dependent kinase 7 (CDK7) dominant negative (DN) or the
vector control were counted 2 days following infection. A 10-cm plate of TGR
cells was transfected with 24 l 1.2 nM small interfering RNA (siRNA; Dhar-
macon) (scrambled control, Myc siRNA#1 or Myc siRNA#2; sequences avail-
able upon request). After 24 h, cells were processed as appropriate.
Microarrays. RNA was harvested from two independent cultures of myc null
rat fibroblasts (HO15.19) expressing the vector control, MycWT, MycMBII,
and MycBM using an RNeasy kit (QIAGEN). RNA integrity and concentration
were verified by gel electrophoresis. Arrays were performed as described previ-
ously (14). Only genes with a signal 20% above background and with at least
70% good data across the arrays were considered for further analysis. The data
were centered to the average of the two vector-only arrays and filtered for
average changes in signal for either MycWT or mutants.
Immunoprecipitations. To detect Myc/Max interactions in myc/ cells, a
15-cm plate of cells was lysed in 1 ml F buffer (53) and extracts incubated with
anti-FLAG antibody-conjugated beads (Sigma) for 3 h at 4°C. Immunoblot
analyses were performed on immunoprecipitated protein using anti-N-Myc or
anti-Max polyclonal antibody (Santa Cruz). To detect Myc/CDK7 interactions in
293 cells, a 10-cm plate of 293 cells was transfected with 1 g expression vector
for N-MycWT or N-MycMBII and 1 g expression vector for CDK7 or the
relevant vector control. After 2 days, nuclei were prepared by hypotonic lysis and
extracted with Dignam C buffer. Extracts were mixed 1:1 with F buffer, and 25%
of each extract was used for an immunoprecipitation (IP) using polyclonal anti-
CDK7 or anti-N-Myc antibody (Santa Cruz). Immunoblot analyses were per-
formed on immunoprecipitated protein using monoclonal anti-CDK7 (Santa
Cruz) or N-myc (Upstate) antibody. For the CDK-activating kinase (CAK) assay,
CDK7 kinase activity was measured as described previously (32) using recombi-
nant CDK2 (Santa Cruz) as a substrate. To detect endogenous Myc/CDK7
interactions in 293 cells, nuclei from 4- by 15-cm plates were extracted with
Dignam C buffer. Cell extracts were mixed 1:1 with F buffer and precleared for
1 h using anti-mouse antibodies. The nuclear extract was divided, and immuno-
precipitation was carried out with either anti-c-Myc antibodies (C33; Santa Cruz)
or control monoclonal antibodies. Western blot analyses were performed as
described above.
Chromatin immunoprecipitation. The Upstate chromatin immunoprecipita-
tion (ChIP) assay kit was used. IPs were carried out using polyclonal anti-FLAG
antibody (Sigma) and polyclonal antibodies raised against N-Myc, MAT1, p62, or
control antibody (Santa Cruz). PCR was carried out on the resultant DNA
samples and 1% of the input using 32P end-labeled primer pairs (sequences
available upon request). PCR products were resolved on 5% Tris-borate-EDTA–
polyacrylamide gel electrophoresis (PAGE), visualized by a phosphorimager,
and quantitated using ImageQuant software. For each reaction, at least three
independent ChIPs were performed and the PCRs were monitored to be well
within the linear range.
RT-PCR. RNA was extracted from log-phase cells by using the RNeasy kit
(QIAGEN) and normalized. Reverse transcription (RT)-PCR was carried out
using the Platinum quantitative RT-PCR system (Invitrogen). The annealing
temperature was 55°C, and the number of cycles to meet the linear range of the
reaction for all primers pairs was determined (typically between 18 and 22). The
primer sequences are available upon request. Products were quantitated as
described above. The mean expression for two independent RNA samples was
calculated, with error bars indicating standard deviations.
Polysome preparation. Polysomes were prepared from log-phase cells by cell
extract centrifugation over 30% sucrose as described previously (9). RNA was
extracted using TRIzol from the monosome/hnRNA fraction at the sucrose
buffer interface and from the polysome pellet. The distribution of specific
mRNAs in each fraction was determined by performing RT-PCR.
Anti-methyl cap IP. RNA was extracted by TRIzol followed by phenol-chlo-
roform, and 2 g was suspended in 100 l binding buffer (25 mM Tris, pH 7.5,
10 mM MgCl2, 1 mg/ml tRNA [baker’s yeast; Roche], 0.1 mg/ml bovine serum
albumin). Anti-2,2,7-methylguanosine antibody-bound beads or antibody con-
trol-bound beads (Calbiochem) were blocked with binding buffer. RNA was
rotated for 1 h at 4°C with 20 l anti-2,2,7-methylguanosine antibody-bound
beads or 40 l antibody control-bound beads to control for nonspecific binding.
Beads and flowthrough were separated, and the volume was increased to 200 l
by adding binding buffer. Samples were extracted with phenol-chloroform, pre-
cipitated with ethanol, and resuspended in 50 l H2O. Two microliters of RNA
was used for each 20-l RT-PCR volume, and RT-PCR was performed as
described above except that 24 to 27 cycles were used.
Immunoblots. Two days following seeding, subconfluent cells were lysed in a
modified radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl, pH
8.0, 130 mM NaCl, 1% NP-40, 0.5% deoxycholate, 0.1% sodium dodecyl sulfate
[SDS], 20 mM NaF, 1 g/ml of leupeptin, pepstatin, and aprotinin, 1 mM
dithiothreitol, and phosphatase inhibitor cocktails I and II [Sigma]). Protein
concentration was determined using a modified Lowry protein assay kit (Pierce).
Equivalent amounts of protein were subjected to SDS-PAGE, transferred to a
polyvinylidene difluoride membrane, and immunoblotted using antibodies raised
against the proteins indicated in the figures. To detect RNA Pol II, nuclei were
isolated by Dounce homogenization of the cell pellet in Dignam A buffer.
Nuclear proteins were extracted by resuspension in Dignam C or F buffer.
Equivalent amounts of protein were immunoblotted for RNA Pol II (Santa
Cruz) and anti-CTD phospho-S5 (H14) and anti-CTD phospho-S2 (H5)
(Covance).
EMSA. An electrophoretic mobility shifty assay (EMSA) was performed as
previously described (53). Complexes were identified by incubating 0.2 g of the
relevant polyclonal antibody with the reaction mixes to assay for supershift or
loss of the band (not shown). Complexes were separated on a 5% acrylamide gel
and visualized by a phosphorimager.
In vivo cell labeling experiments. For each IP, a 10-cm plate of myc/
fibroblasts or myc/ fibroblasts expressing MycWT, MycBM, MycC, or the
vector control was incubated for 30 min in 4 ml Dulbecco modified Eagle
medium without cysteine and methionine (Sigma) and in 10% dialyzed fetal calf
serum. Promix (10 l; Amersham) was added for 0.5, 1, or 1.5 h as indicated.
Chase was performed by washing the cells three times and incubating them in
normal growth medium for 2, 4, or 6 h as indicated. RIPA extracts were made
and normalized for protein content. Samples were precleared by 1 h of incuba-
tion with 25 l normal rabbit immunoglobulin G agarose. Polyclonal cyclin T1 or
CDK9 antibody (1 g) was incubated with the extracts overnight, and then 25 l
protein A/G-Sepharose was added for 1 h. Beads were washed in RIPA buffer
and eluted in sample buffer. Immunoprecipitated protein and cell extracts were
resolved on 8% SDS-PAGE. Bands were visualized using a Storm phosphor-
imager and quantitated using ImageQuant software. Each experiment was per-
formed on at least two independent occasions. The experiment whose results are
shown is representative, and error bars indicate the standard deviations for
duplicates. Total label incorporation was calculated by trichloroacetic acid
(TCA) precipitation of cell extracts, followed by label detection using a scintil-
lation counter.
RESULTS
Design and characterization of Myc mutants defective for
DNA binding. We are interested in the biological activity of the
Myc transactivation domain and wanted to separate the func-
tion of this domain from the downstream effects of Myc target
genes. Such analysis can reveal novel Myc activities as well as
provide insight into wild-type Myc function. To this end, we
created two mutants of murine N-Myc, called MycBM and
MycC, which could not bind to DNA directly (Fig. 1A). In
MycBM, the C-terminal, basic region which binds to the DNA
phosphate backbone is mutated into an acidic region, i.e.,
amino acids 381 to 384, RQRR, are mutated to ADAA.
MycC has a deletion of the entire DNA binding and Max
dimerization domain (amino acids 372 to 454) and a nuclear
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FIG. 1. DNA binding-deficient Myc mutants. (A) A diagram of
murine N-Myc mutants. MycMBII has a deletion of amino acids 103
to 119. MycBM has amino acids 381 to 384 mutated from RQRR to
ADAA. MycBMMBII has both previous mutations. MycC is trun-
cated at amino acid 370 and has a nuclear localization signal (NLS) at
the C terminus. DNA binding in EMSA and Max binding in coimmu-
noprecipitation are summarized. (B) Myc proteins were immunopre-
cipitated from reconstituted myc/ cells using anti-FLAG antibody
and immunoblotted for N-Myc and Max (upper panels). Cell extracts
were immunoblotted for Max (lower panel). (C) EMSA was per-
formed on extracts from 293 cells expressing the indicated Myc pro-
teins, using a Myc/Max consensus binding site probe. Extracts were
also immunoblotted with anti-FLAG to detect the Myc proteins (upper
panel). (D) RNA extracted from myc/ cell lines expressing the
indicated Myc protein was used for RT-PCR using primers specific for
the Myc-activated CAD, HSP60, and nucleolin (NUCL) genes, the
Myc-repressed neomycin (Neo) (under the control of the c-myc pro-
moter) and GADD45 genes, and GAPDH as a control. (E) The same
RNA was hybridized to rat oligonucleotide microarrays (see Materials
and Methods). The graph shows the relative expression levels of Myc
target genes in response to MycWT, MycMBII, and MycBM com-
pared to that of the vector control. When the expression levels of the
samples were compared to those of the vector control, the t test
returned the following P values: MycWT, 1.4  107; MycMBII, 0.09;
and MycBM, 0.5. WB, Western blot; USF, upstream stimulatory
factor.
VOL. 27, 2007 Myc PROMOTES RNA Pol II CTD PHOSPHORYLATION 2061
localization signal added at the C terminus. These two DNA
binding mutants were designed to be complementary. MycBM
retains the Max binding domain whereas MycC does not.
Equivalent cellular responses to the expression of both mu-
tants are unlikely to be due to Max titration. To further inves-
tigate the role of the N terminus of Myc, an additional deletion
of amino acids 103 to 119, encompassing the Myc homology
box II domain (MBII), was made in the full-length Myc and
MycBM proteins, creating MycMBII and MycBMMBII, re-
spectively. MBII is highly conserved in evolution and is neces-
sary for nearly all reported N-terminal interactions and func-
tions, including oncogenic transformation (54).
We confirmed that MycBM and MycC did not bind to the
Myc consensus sites or regulate Myc target genes and that they
bound to Max as predicted. To assess Max interaction, Myc
proteins were immunoprecipitated via their FLAG tag and
immunoblotted for Myc and Max (Fig. 1B). As predicted,
MycWT, MycBM, and their respective MBII mutants were
able to bind to endogenous Max, whereas MycC could not.
Since MycBM retains much of the DNA binding domain, we
wanted to confirm that it could not bind to Myc consensus
sites. An EMSA was performed using transiently expressed
proteins and the Myc/Max consensus binding site, CACGTG,
as a probe. MycWT, MycMBII, and MycBM were expressed
at equivalent levels (Fig. 1C, upper panel). In the EMSA,
Myc/Max and MycMBII/Max heterodimers could bind to a
CACGTG probe and were detected as a characteristic band
that migrated faster than the endogenous upstream stimula-
tory factor-DNA complex. MycBM did not have detectable
DNA binding activity, despite the fact that it dimerized avidly
with Max (Fig. 1B). The presence of both Myc and Max in the
DNA binding complexes was confirmed by a supershift using
anti-Max and anti-Myc antibodies (data not shown).
To confirm that MycBM was not regulating Myc target
genes, the transcription of many established Myc-activated and
-repressed genes was measured (Fig. 1D and E). Quantitative
RT-PCR was performed on RNA extracted from pools of myc
null cells expressing MycWT, MycMBII, and MycBM.
MycWT was found to increase transcription of the established
Myc-activated CAD, HSP60, and nucleolin genes two- to
threefold, but MycBM did not increase the transcription of
these genes above background levels (Fig. 1D). Transcription
of established Myc-repressed genes, the GADD45 and endog-
enous c-myc (reported by the neomycin gene driven by the
c-myc promoter in myc null cells) genes, were repressed about
fivefold by MycWT, but MycBM failed to repress either target.
Microarray analysis concurred that MycBM does not activate
Myc target genes. Previously, Myc target genes in the rat
fibroblast system had been established using microarrays and
auxiliary techniques (43). We found 21 previously reported
Myc target genes to be upregulated by the expression of
MycWT in our experiments (Fig. 1E). In contrast, the expres-
sion of MycBM does not upregulate any of these genes, and
the vector control values and MycBM values are not signifi-
cantly different, giving a P value of 0.4 using the t test. An
equivalent microarray analysis of the transcriptional response
to MycC was carried out and showed that MycC also does
not upregulate Myc target genes (not shown).
Recent findings have shown that Myc is a regulator of rRNA
synthesis, and it is hypothesized that this has a role in mediat-
ing the Myc growth phenotype (3, 21, 22). We found that the
expression of MycWT increased total RNA content per cell
(the majority of which is rRNA) about 1.5-fold above that of
vector control cells (not shown). As predicted from the obser-
vation that MycBM cannot activate target genes, the expres-
sion of MycBM did not elevate cellular RNA content.
Myc induces morphological changes independently of target
gene expression. To investigate the activity of the Myc N ter-
minus independent of target genes, MycWT and the DNA
binding mutants were stably expressed in the myc null rat
fibroblast cell line HO15.19 (31). The myc/ background al-
lows Myc mutant phenotypes to be revealed rather than
masked by endogenous Myc. Equivalent expression levels of
the Myc proteins were verified by immunoblotting (Fig. 1B).
myc/ fibroblasts are broad, flat, and nonrefractile. As previ-
ously reported, the expression of MycWT reverted the myc/
cell morphology to become comparable to that of Rat1 fibro-
blasts, the myc/ line from which the myc/ cells were
derived (31). The MycWT-reconstituted cells appear smaller
(although their volume is unchanged), darker, and refractile
(Fig. 2A). MycWT cells also grew to a higher density than the
vector control myc/ cells (not shown). Surprisingly, the ex-
pression of MycBM partially rescued the morphology of
myc/ cells. MycBM cells appeared darker, smaller, and more
refractile than vector control cells (Fig. 2A). They were also
FIG. 2. DNA binding-deficient Myc mutants induce cell prolifera-
tion and morphological change. The results of an analysis of myc/
cells expressing MycWT and mutants are shown. (A) Phase-contrast
micrographs of log-phase cells. (B) Growth curves. The data shown
represent the means for at least three experiments, and error bars
show the standard deviations.
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able to grow to a higher density than vector cells (not shown).
This phenotype was immediately apparent upon the expansion
of polyclonal cell populations and reproduced in three inde-
pendent infections. The morphological changes driven by
MycBM were completely dependent on an intact N terminus
because MycBMMBII cells had the same morphology as vec-
tor control cells (Fig. 2A). Therefore, the N terminus of Myc
can partially rescue myc/ cell morphology independently of
direct DNA binding and target gene expression.
The proliferation defect in myc/ cells can be partially
rescued by Myc DNA binding mutants. Cell proliferation is
dependent on Myc expression, and therefore, we investigated
whether MycBM and MycC could rescue the proliferation
defect of myc/ cells. The doubling times of the cell lines
were measured by counting equivalently seeded cells on con-
secutive days (Fig. 2B). In line with previous publications,
myc/ cells had a doubling time of 40 h and MycWT-express-
ing cells had a doubling time of 19 h (31). The expression of
both MycBM and MycC resulted an intermediate doubling
time of 28 h. Thus, a significant proportion of the growth
defect in myc/ cells can be restored by Myc proteins that
cannot regulate target gene transcription. Consistent with mor-
phological changes, this proliferation rescue was dependent on
an intact N terminus, since the MycBMMBII cells had a
doubling time of 36 h, close to that of the vector control.
Moreover, this proliferative activity is independent of Max
titration, since MycBM can bind to Max whereas MycC can-
not. The ability of Myc DNA binding mutants to rescue the
myc/ cell proliferation defect was confirmed by cell cycle
analysis using propidium iodide staining and fluorescence-ac-
tivated cell sorter analysis (not shown). MycBM and MycC,
unlike MycWT, do not rescue the growth defect in serum-
starved cells and do not induce apoptosis or cell transforma-
tion (not shown).
Myc increases total cellular CAK activity. Having demon-
strated a potent biological activity for the Myc N terminus, we
were interested in resolving the mechanism of this activity and
its relationship to wild-type Myc function. Myc-induced cell
proliferation is correlated with an increase in cell cycle CDK
activity (32). CDK complexes are activated by CAK, which
phosphorylates the CDK T loop (23, 37). Since we had found
that the expression of MycBM and MycC accelerated prolif-
eration in a target gene-independent manner, we investigated
whether total cellular CAK activity is increased in response to
the expression of MycWT and mutants by using a CAK assay
(Fig. 3A). The CAK assay only indicates the level of CAK
activity in a cell line and does not distinguish increases in the
specific activity of CAK from increases in the concentration of
CAK itself, which are addressed below. CAK was immunopre-
cipitated from cell extracts by using an anti-CDK7 antibody
and incubated with CDK2 as a substrate (Fig. 3A). In the
representative assay whose results are shown, CAK activity in
MycWT cell extracts was found to be 1.9-fold over that of the
vector control, as reported previously (32). CAK activity was
also elevated in MycBM cell extracts (1.7-fold over that of the
vector control). Increased CAK activity was dependent on an
intact N terminus because extracts from MycBMMBII cells
have the same level of kinase activity as vector control cells
(0.8-fold). In correlation with increased total cellular CAK
activity, we found elevated levels of phospho-CDC2 and phos-
pho-CDK2 in cells expressing MycWT, MycBM, and MycC
compared to those in the vector control and MycBMMBII
(not shown).
To demonstrate that CAK has a critical role in cell prolif-
eration and T-loop phosphorylation in vivo, we expressed a
catalytically inactive CDK7 mutant, CDK7D155N, in the
myc/ fibroblast cell line TGR (28). Expression of this dom-
inant interfering CDK7 inhibited both CDC2 and CDK2 phos-
phorylation levels and CDK2 expression (Fig. 3B). The cell
proliferation rate was also inhibited by CDK7D155N (Fig. 3C).
Myc increases CAK expression independently of Myc target
genes. CAK is a complex of CDK7, cyclin H, and MAT1. We
investigated whether the increased CAK activity found in Myc-
expressing cells could be a result of increased CAK component
protein expression (Fig. 4A). To investigate whether CAK com-
ponent expression was upregulated in response to endogenous
Myc expression, we compared the parental myc/ fibroblasts
with myc/ fibroblasts and we used two independent Myc
siRNAs to knock down endogenous Myc expression in myc/
fibroblasts. Both cyclin H and MAT1 expression levels were re-
FIG. 3. The DNA binding-deficient Myc mutant elevates total cel-
lular CAK activity. (A) A CAK assay was performed on extracts from
myc/ fibroblasts expressing the indicated Myc protein. Protein im-
munoprecipitated with anti-CDK7 or control antibody was incubated
with recombinant CDK2 and [32P]ATP, and reaction products were
run on a gel, visualized by a phosphorimager (left panel), and quan-
titated (right panel). The results of a representative experiment are
shown. (B) Cell extracts were prepared from myc/ fibroblasts (TGR)
expressing the vector control and CDK7 DN as indicated. Extracts
were immunoblotted using antibodies raised against phospho-CDC2
(CDC2-P), CDC2, phospho-CDK2 (CDK2-P), CDK2, and -tubulin
(Tub). (C) Growth curves for myc/ fibroblasts (TGR) expressing the
vector control and CDK7 DN. The data shown represent the means for
two experiments, and error bars show the standard deviations.
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duced in myc/ fibroblasts compared to those in myc/ cells
and myc/ cells transfected with both Myc siRNAs but not the
control siRNA. Next, we investigated CAK component expres-
sion in response to exogenous MycWT and the DNA binding
mutants. In agreement with previous reports, we found a substan-
tial increase in CDK7, cyclin H, and MAT1 protein expression in
response to exogenous MycWT (32). Interestingly, we also found
a comparable increase in CAK protein expression in cells express-
ing MycBM and MycC. These effects were dependent on an
intact N terminus because cells expressing MycMBII and
MycBMMBII did not express increased levels of CDK7, cyclin
H, and MAT1. Thus, the increased cellular CAK activity in
MycWT-, MycBM-, and MycC-expressing cells can be well cor-
related with elevated protein expression, and it is unlikely that the
specific activity of CAK itself increases.
We wanted to determine how CAK components were being
upregulated in response to Myc. CDK7 and MAT1 have never
been reported as Myc target genes, and cyclin H is reported
as a Myc-repressed gene (http://www.myc-cancer-gene.org) (49).
However, we wanted to determine whether the transcription of
these genes is activated in our specific cell system. Although the
MycBM and MycC proteins lack DNA binding activity and
activation of traditional Myc target genes, it was possible that they
could upregulate the transcription of members of the CAK com-
plex indirectly. We measured mRNA levels by a carefully con-
trolled quantitative RT-PCR, carried out in the linear range on
FIG. 4. Myc induces CAK expression by a posttranscriptional mechanism. (A) Cell extracts were prepared from myc/ or myc/ fibroblasts
expressing the indicated Myc protein from several cell systems: myc/ fibroblasts transfected for 24 h with control siRNA or two independent Myc
siRNAs, a neuroblastoma cell line (Tet-21/N) expressing doxycycline-off N-Myc cultured in 0 and 0.2 g/ml doxycycline (Dox) for 2 days, and
IMECs expressing c-MycWT or c-MycMBII. Immunoblot analyses were performed on cell extracts using antibodies raised against CAK
components, CDK7, cyclin H, and MAT1, and -tubulin (Tub). Immunoblot analyses were also performed using anti-c-Myc antibodies on myc/
cell extracts and IMEC extracts and using anti-N-Myc antibodies on neuroblastoma cell extracts. (B) RNA was extracted from two independent
log-phase samples. RT-PCR was performed in the linear range using primers specific for CDK7, cyclin H, MAT1, and GAPDH. Mean relative
expression levels were calculated, and error bars indicate the standard deviations.
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FIG. 5. Myc induces RNA Pol II phosphorylation. Nuclear extracts
were prepared from the following log-phase cells: (A) myc/ fibroblasts,
myc/ fibroblasts expressing the indicated Myc protein, myc/ fibro-
blasts transfected with control siRNA or two independent Myc siRNAs,
(B) a neuroblastoma cell line (Tet-21/N) expressing N-Myc cultured in 0
and 0.2 g/ml doxycycline (Dox) for 2 days, and (C) IMECs expressing the
indicated Myc protein. Immunoblot analyses were performed using
monoclonal antibodies (mAb) raised against RNA Pol II CTD phos-
pho-S5 (H14) and phospho-S2 (H5) and the RNA Pol II large subunit.
(D) Immunoblot analyses were performed on cell extracts using antibod-
ies raised against P-TEFb components, CDK9 and cyclin T1, and -tu-
bulin (Tub). (E) RT-PCR was performed in the linear range using prim-
ers specific for CDK9 and cyclin T1 on RNA from two independent
samples. Mean relative expression levels were calculated, and error bars
indicate the standard deviations.
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independent RNA samples. We found that CDK7, cyclin H, or
MAT1 mRNA was not induced in response to modulation of
endogenous Myc expression, both when comparing myc/ with
myc/ fibroblasts and in response to both Myc siRNAs (Fig. 4B).
We also looked at CAK component expression in response to
exogenous MycWT and DNA binding mutants. We found that
CDK7, cyclin H, or MAT1 mRNA was not induced in cells ex-
pressing MycBM or MycC compared to that in the vector con-
trol (Fig. 4B). These results were confirmed by microarray anal-
ysis (not shown). There was also no induction of CDK7 or cyclin
H by MycWT. MAT1 mRNA was elevated in response to exog-
enous MycWT (and not in response to endogenous Myc levels).
We conclude that endogenous Myc and the transcription-defec-
tive mutants MycBM and MycC lead to elevated CAK expres-
sion through a posttranscriptional mechanism.
We were interested in whether CAK protein expression was
Myc responsive in other cell systems. We investigated CAK
expression in cells from other lineages and in response to
c-Myc as well as N-Myc. We examined CAK subunit expres-
sion in Tet-21/N cells, a neuroblastoma cell line that expresses
N-Myc under doxycycline regulation (27), and in IMECs, a
low-passage immortalized mammary epithelial line, engi-
neered to stably express exogenous c-MycWT or c-MycMBII
(17). We found increased expression of CDK7, cyclin H, and
MAT1 proteins in response to elevated N-Myc expression in
the neuroblastoma cell line and in response to elevated c-
MycWT but not c-MycMBII in the IMECs (Fig. 4A). In
agreement with the fibroblast data, Myc-driven upregulation of
these proteins was found to be entirely posttranscriptional.
CDK7, cyclin H, or MAT1 mRNA was not Myc regulated in
either cell line (Fig. 4B). For the mammary epithelial cell line,
this result was also confirmed by microarray analysis of RNA
extracted from log-phase cells (not shown).
In summary, Myc can increase the expression of CAK pro-
teins by a posttranscriptional mechanism in a variety of cell
lines, in response to exogenous and endogenous Myc levels,
and in response to both c-Myc and N-Myc.
Myc expression elevates cellular TFIIH and P-TEFb activity
by a posttranscriptional mechanism. The CAK components
CDK7, cyclin H, and MAT1 are also components of the basal
transcription factor TFIIH. CDK7 is the TFIIH kinase which
phosphorylates the RNA Pol II CTD S5 (52). Since we had
found elevated CAK expression in response to Myc, we inves-
tigated whether this also led to increased TFIIH kinase activ-
ity. The protein expression level of RNA Pol II large subunit
was unaltered in response to modulation of Myc expression in
rat fibroblasts, the Tet-21/N neuroblastoma, and IMEC lines
(Fig. 5, bottom panels). However, Myc expression was rate
limiting for RNA Pol II CTD S5 phosphorylation, as detected
by phospho-specific antibodies (Fig. 5A). S5 phosphorylation
was reduced in myc/ fibroblasts compared to that in myc/
fibroblasts and was also reduced in myc/ fibroblasts in which
endogenous Myc was knocked down by two siRNAs. CTD S5
phosphorylation was also elevated in response to the expres-
sion of exogenous MycWT in fibroblasts, neuroblastoma cells,
and epithelial cell lines (Fig. 5A to C). Furthermore, S5 phos-
phorylation was increased in response to the expression of the
transcription-defective mutants MycBM and MycC but not
MycBMMBII (Fig. 5A). Therefore, Myc-induced CTD S5
phosphorylation is dependent on the Myc N terminus alone
but is also induced by MycWT. It is important to stress that the
elevated CTD phosphorylation found in Myc-expressing cells
is sufficiently large to be detected in the total nuclear pool of
RNA Pol II. Thus, TFIIH is Myc regulated and rate limiting
for CTD phosphorylation.
The S2 position of the RNA Pol II CTD is also phosphory-
lated, predominantly by P-TEFb. P-TEFb consists of CDK9
and several cyclins, most commonly cyclin T1. We found that
Myc expression upregulates the subunits of P-TEFb (Fig. 5D).
Endogenous Myc expression in fibroblasts elevated CDK9 and
cyclin T1 protein expression levels since expression was higher
in control myc/ cells than in myc/ cells with Myc knocked
down or in myc/ cells. Overexpression of MycWT in myc/
fibroblasts, the Tet21/N neuroblastoma line, and the IMEC
line also increases expression of CDK9 and cyclin T1 (Fig. 5D).
Again, elevated expression was dependent on the Myc N ter-
minus alone since MycBM and MycC but not MycBMMBII
induced increased CDK9 and cyclin T1 protein expression
levels. As with TFIIH, the elevation in CDK9 and cyclin T1
proteins was not mediated by elevated mRNA levels (Fig. 5E).
The Myc-dependent increase in P-TEFb expression corre-
lated with RNA Pol II S2 CTD phosphorylation. S2 phosphor-
ylation was reduced upon the loss of endogenous Myc expres-
sion and increased upon the expression of MycWT, MycBM,
and MycC in rat fibroblasts. S2 phosphorylation was also
elevated in neuroblastomas with high N-Myc levels and in
IMECs overexpressing MycWT or MycC (Fig. 5). Again, we
stress that the elevated S2 phosphorylation was found in the
total nuclear pool of RNA Pol II.
In summary, both S5 and S2 phosphorylation levels in the
RNA Pol II CTD are increased in response to exogenous and
endogenous Myc expression. Mutant analysis demonstrated
that this is dependent on an intact N terminus but independent
of direct Myc DNA binding and target gene expression.
Myc increases the translation rate of cyclin T1 and CDK9.
The findings above demonstrate that Myc can increase the
expression of a subset of CDKs and cyclins by a posttranscrip-
tional mechanism and independently of Myc target gene ex-
pression. Next, we investigated whether these proteins were
being upregulated as a result of an increased translation rate or
a decreased degradation rate. We used pulse-chase experi-
ments to compare the translation rates and degradation rates
of the P-TEFb complex proteins CDK9 and cyclin T1. We
measured these rates in the parental myc/ fibroblasts and
myc/ fibroblasts expressing exogenous MycWT, MycMBII,
MycBM, MycC, and the vector control. The decision to in-
vestigate P-TEFb rather than CAK and TFIIH was technical,
i.e., in pulse-chase experiments, the simple P-TEFb het-
erodimer was more amenable to the resolution of individual
protein components than the multisubunit TFIIH.
Cells were pulse-labeled with [35S]methionine and [35S]cys-
teine for 0.5, 1, or 1.5 h, followed by a chase with cold amino
acids for 2, 4, or 6 h. Cell extracts from each time point were
normalized for protein content. To measure total cellular label
incorporation for each time point, protein was precipitated
using TCA and the counts were quantitated (Fig. 6A). Label
incorporation during the pulse was approximately 1.5-fold
higher in myc/ cells than in myc/ cells (P  0.1). Label
incorporation into myc/ cells expressing MycWT, MycBM,
MycC, and the vector control was statistically indistinguish-
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able (P  0.1). Label loss during the chase was lowest for
myc/ cells and highest for myc/ cells and myc/ cells
expressing MycWT, but the values were statistically indistin-
guishable (P  0.1). To measure label incorporation into
CDK9 and cyclin T1 at each time point, these proteins were
FIG. 6. Myc elevates cyclin T1 and CDK9 translation rate, poly-
some loading, and mRNA cap methylation. Log-phase myc/ fibro-
blasts and myc/ fibroblasts expressing MycWT, MycBM, MycC, or
the vector control were labeled (“pulse”) with [35S]methionine/cys-
teine for 0.5, 1.0, or 1.5 h. Subsequently, cells were washed and incu-
bated in regular growth medium (“chase”) for 6 h. Cell extracts were
prepared and normalized for protein content. (A) Protein was precip-
itated from cell extracts using TCA and the counts detected using a
scintillation counter. The left panel represents label incorporation
(Incorp.) during “pulse,” and the right panel represents label loss
during “chase.” (B) Cyclin T1 and CDK9 were immunoprecipitated
from cell extracts, resolved on SDS-PAGE, and visualized by a phos-
phorimager. (C) Mean quantitation of duplicates from a representa-
tive experiment is shown. Error bars show the standard deviations. The
upper panels indicate relative label incorporation into cyclin T1 and
CDK9 during “pulse,” and the lower panels indicate label loss during
“chase.” (D) Using the same cell lines as described above, polysomes
were separated from monosomes/hnRNA by centrifugation through a
sucrose bed. The proportion of 18S rRNA in the polysome fraction
and monosome fraction was calculated. mRNA from each fraction was
used as substrate for RT-PCR for the mRNA indicated. The propor-
tion of each mRNA in polysome and monosome fractions for each cell
line is depicted. The results of a representative experiment are shown.
Mean values of duplicates are shown, and error bars indicate the
standard deviations. (E) Protein extracts made from the same panel of
cell lines were used to perform Western blot analyses, probing with
anti-RUVBL1 and anti-nucleolin (NUCL) antibodies. RT-PCR was
performed on independently isolated RNA samples from the same
cells by using primers specific for RUVBL1 and nucleolin. (F) Cap
methylation was assessed for RNA extracted from myc/ fibroblasts
expressing the vector control, MycWT, and MycC and from immor-
talized mammary epithelial cells expressing the vector control and
MycWT. RNA was subjected to immunoprecipitation using anti-2,2,7-
methylguanosine antibody. RNA was purified and used as a template
for RT-PCR using primers specific for the genes indicated. The quan-
tity of immunoprecipitated RNA is expressed as a fraction of input
RNA. The results of representative experiments are shown.
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immunoprecipitated and resolved by SDS-PAGE. Label incor-
poration was detected and quantitated using a phosphorimager
(Fig. 6B and C). During the pulse, the rate of label incorpo-
ration into cyclin T1 was found to be approximately 4.5-fold
higher in myc/ cells than in myc/ cells and approximately
2.5-fold higher in myc/ cells expressing MycWT, MycBM, or
MycC than in cells expressing the vector control (P  0.1).
Similarly, the rate of label incorporation into CDK9 during the
pulse was found to be approximately 5.5-fold higher in myc/
cells than in myc/ cells and approximately 3-fold higher in
myc/ cells expressing MycWT, MycBM, or MycC than in
cells expressing the vector control (P  0.1). Label incorpora-
tion into cyclin T1 and CDK9 in cells expressing MycMBII
was indistinguishable from incorporation in vector control cells
(see Fig. S1 in the supplemental material). During the chase,
label losses from cyclin T1 were similar for all cell lines but
actually slowest for myc/ cells compared to those for all
other cell lines tested, i.e., cyclin T1 was most stable in myc/
cells. Total label loss from CDK9 was statistically indistinguish-
able for all cell lines (P  0.1). Since cyclin T1 degradation is
actually slowest in myc/ cells and CDK9 degradation rates
are equivalent in all cell lines tested, the increased labeled
amino acid incorporation during the pulse in cells expressing
endogenous Myc, exogenous MycWT, MycBM, and MycC
can be concluded to be a reflection of an increased translation
rate. In addition, the increased translation rate is dependent on
MBII, since label incorporation in cyclin T1 and CDK9 is
indistinguishable for MycMBII and the vector control.
We demonstrated above that Myc upregulates CAK sub-
units by a posttranscriptional mechanism as with P-TEFb. One
or more CAK components may also be upregulated at the level
of translation; however, due to the complexity of CAK and
TFIIH, it was not possible to investigate the translation rates of
these complexes by pulse-chase experiments.
Myc increases polysome loading of cyclin T1, CDK9, and
specific Myc target genes. Efficiently translated mRNAs are
found to be associated with polysomes rather than mono-
somes. Since we had shown that CDK9 and cyclin T1 are
translated more rapidly in response to Myc, we expected to see
a correlative increase in polysome loading. We used centrifu-
gation over a sucrose bed to separate monosomes/hnRNA
from polysomes in the fibroblast cell lines (9). Initially, we
quantitated 18S rRNA distribution as a measure of ribosome
distribution (Fig. 6D). For all cell lines, the 18S rRNA was
found predominantly in the monosome fraction. Vector con-
trol myc/ cells had a slight decrease in the proportion of 18S
rRNA found in the polysome fraction compared to the Myc-
expressing cell lines. mRNA extracted from polysome and
monosome fractions was used as a substrate for RT-PCR to
look at the distribution of specific messages (Fig. 6D). In
myc/ cells, less than 50% of the cyclin T1 mRNA was asso-
ciated with polysomes, whereas in myc/ cells and in myc/
cells expressing MycWT, MycBR, and MycC, approximately
90% of the cyclin T1 mRNA was associated with polysomes.
The same trend was found with CDK9. In myc/ cells, less
than 10% of the CDK9 mRNA was associated with polysomes,
whereas in all Myc-expressing cell lines, approximately 50% of
the CDK9 mRNA was associated with polysomes. The in-
creased association of cyclin T1 and CDK9 with polysomes in
response to exogenous and endogenous MycWT and in re-
sponse to Myc DNA binding mutants is consistent with the
increased translation rate of these mRNAs in Myc-expressing
cells.
The data above document a novel, target gene-independent
activity of Myc; however, we also wanted to explore the pos-
sibility that Myc could influence polysome loading of tradi-
tional Myc target genes, i.e., increase both the transcription
and the translation of some genes. We investigated the poly-
some loading of three genes which have been established as
Myc target genes in rat fibroblasts, the HSP60, RUVBL1, and
nucleolin genes (43). We confirmed that the transcription of all
three of these genes was upregulated in response to MycWT
but not the Myc DNA binding mutants (Fig. 1D and data not
shown). For all three mRNAs, polysome loading was increased
in myc/ cells compared to that in myc/ cells and was
increased in response to exogenous MycWT. For HSP60
mRNA, the increase in polysome loading was mild, increasing
from 35% in myc/ cells to 50% in myc/ cells, and there
was no increased polysome loading in response to the DNA
binding mutants. However, for nucleolin and RUVBL1, the
effect was more significant, and polysome loading was in-
creased in response to the Myc DNA binding mutants as well
as the wild-type protein. This differential effect of Myc and
Myc mutants is discussed later. Polysome loading for GAPDH
(glyceraldehyde-3-phosphate dehydrogenase) mRNA was not
significantly Myc dependent. In myc/ cells expressing the
vector control and Myc proteins, about 40% of GAPDH
mRNA was found to be polysome associated. The parental
myc/ line had a mild increase of up to 60% GAPDH mRNA
that was polysome associated.
Since the percentage of polysome loading of nucleolin and
RUVBL1 is increased in response to MycWT and Myc DNA
binding mutants, the prediction is that the expression of
nucleolin and RUVBL1 protein will be increased in response
to both MycWT and the Myc DNA binding mutants. We per-
formed Western blot analyses on our panel of rat fibroblast cell
lines by using anti-RUVBL1 and antinucleolin antibodies (Fig.
6E). As predicted, we saw increased expression of both pro-
teins in response to endogenous and exogenous MycWT and in
response to MycBM and MycC compared to that in myc/
cells. The increase in protein expression was larger in response
to MycWT than in response to the Myc DNA binding mutants.
This is consistent with the fact that these are also Myc tran-
scriptional target genes, i.e., nucleolin and RUVBL1 mRNAs
are elevated in response to MycWT but not the DNA binding
mutants (Fig. 6E). Therefore, the increased expression of these
proteins in response to MycWT is likely a result of increased
transcription and increased polysome loading and translation.
The increase in expression is lower in cells expressing MycBM
and MycC, probably because it is a result of increased trans-
lation alone.
Myc increases mRNA cap methylation. Next, we investi-
gated the mechanism by which Myc increases mRNA polysome
loading and translation. We found that the nucleocytoplasmic
distribution of all the mRNAs discussed above was unaltered
by the expression of MycWT or Myc mutants (not shown), and
therefore, Myc does not regulate polysome loading and trans-
lation of these mRNAs by regulating their nuclear export. We
also monitored the expression of a comprehensive panel of
translation initiation and elongation factors and found no dif-
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ferences between MycBM, MycC, and control cells (data not
shown).
Translation of mRNA is dependent on the addition of the
7-methylguanosine triphosphate 5	 cap, which occurs most ef-
ficiently cotranscriptionally (5, 40). Guanylylation stabilizes
mRNA, and methylation permits mRNA translation. (50).
Since we had found a group of genes that were equivalently
expressed at the mRNA level but that were not equivalently
translated, we hypothesized that cap methylation might be
regulated.
To measure the proportion of methylated CDK9 and cyclin
T1 mRNA, we used an anti-2,2,7-methylguanosine antibody
which also binds to 7-methylguanosine (7). RNA isolated from
fibroblasts and epithelial cells expressing MycWT, MycC, and
the vector control was offered as a substrate for immunopre-
cipitations using the anti-methyl cap antibody. The RNA
bound to the anti-methyl cap antibody was isolated, and RT-
PCR was used to calculate the antibody-bound fraction (and
therefore methylation) of each mRNA relative to that of the
input mRNA (Fig. 6F). We found that the proportion of meth-
ylated CDK9 and cyclin T1 mRNA was higher in MycWT or
MycC cells than in the vector control in both fibroblasts and
mammary epithelial cells. We also found that nucleolin but not
HSP60 mRNA cap methylation was significantly increased in
response to MycWT and MycC. This is consistent with
nucleolin but not HSP60 mRNA polysome loading being well
regulated by Myc (Fig. 6D). GAPDH methylation was not
regulated by Myc levels for either cell line, which correlates
with a lack of stimulation of polysome loading in these cells.
Nonspecific binding of mRNA to control antibody beads was
uniform and relatively low, 10% of input RNA. We propose
that the mechanism by which Myc increases the translation
rate of specific messages is by increasing mRNA methyl cap
formation for select genes.
The Myc N terminus is recruited to transcription start sites.
mRNA capping occurs most efficiently cotranscriptionally, and
cap methyltransferase is recruited by the TFIIH-phosphor-
ylated RNA Pol II CTD (25, 48). Therefore, we investigated
whether Myc increases TFIIH recruitment to specific genes, in
correlation with the increased capping, polysome loading, and
translation of these genes. We investigated the in vivo binding
of TFIIH to the cyclin T1, cyclin H, and nucleolin transcrip-
tional initiation sites (the CDK9 promoter proved to be refrac-
tory to PCR). Using ChIP, we found enhanced recruitment of
MAT1 and p62 (subunits of TFIIH) to the cyclin H, cyclin T1,
and nucleolin transcription initiation sites in MycWT-,
MycBM-and MycC-expressing cells compared to that in the
vector control (Fig. 7A). In correlation with the fact that
MycMBII is defective in increasing CDK9 and cyclin T1
translation and expression, enhanced recruitment of TFIIH to
transcription initiation sites was not found in cells expressing
MycMBII (see Fig. S2 in the supplemental material). There
was also no Myc-dependent recruitment of TFIIH to the
GAPDH transcription initiation sites, which also did not have
increased cap methylation and polysome loading.
We had demonstrated that Myc expression increases TFIIH
recruitment and mRNA methylation and that this is an activity
of the N terminus of Myc independent of the DNA binding
domain. We wanted to determine whether Myc could have a
direct role in this process by being recruited to the transcrip-
tion initiation sites via the N terminus. We investigated Myc
binding by ChIP using anti-FLAG and anti-Myc antibodies. To
confirm that MycC was not binding nonspecifically to DNA,
we established that MycWT but not MycC was recruited to
Myc/Max consensus sites in the established HSP60 and nucleo-
lin target genes (Fig. 7B). This confirms that the DNA binding
domain is necessary for direct Myc binding to E-box DNA in
vivo. In contrast, we found that MycMBII, MycBM, and
MycC were recruited to the transcription initiation sites of
cyclin H, cyclin T1, and nucleolin (Fig. 7C and see Fig. S2 in
the supplemental material). Therefore, the Myc N terminus
can be recruited to these transcriptional initiation sites indi-
rectly and independently of the DNA binding domain. The fact
that MycMBII is recruited to transcription initiation sites but
that MycMBII-expressing cells do not have enriched TFIIH
recruitment to these sites suggests that Myc-dependent en-
hanced TFIIH recruitment is dependent on prior MycWT
binding. As a negative control, Myc was not found to be re-
cruited to GAPDH initiation sites (Fig. 7C).
Consistent with the model that MBII recruits TFIIH to the
transcription initiation sites of certain genes, we found that Myc
could be coimmunoprecipitated with CDK7, the kinase subunit of
TFIIH (Fig. 7C). Furthermore, MycWT but not MycMBII
could be coimmunoprecipitated with CDK7 by using an anti-
CDK7 antibody, and CDK7 could be coimmunoprecipitated with
MycWT but not MycMBII by using an anti-Myc antibody. En-
dogenous CDK7 could also be immunoprecipitated with endog-
enous Myc protein from 293 cells (Fig. 7D).
DISCUSSION
Myc increases CTD kinase activity. Here, we report that
Myc induces the expression of both CDK7 and CDK9 kinases,
which phosphorylate the RNA Pol II CTD as components of
TFIIH and P-TEFb, respectively, and that there is a concom-
itant increase in the phosphorylation of their respective sub-
strates, S5 and S2, in the CTD. All of the activities we dem-
onstrate for MycWT are manifested by the Myc transactivation
domain alone and thus are within the repertoire of normal Myc
function but independent of target gene activation. We show
that these kinase activities are induced in response to c-Myc
and N-Myc in fibroblasts, epithelial cells, and neuroblastoma
cells. We also demonstrate that Myc can promote TFIIH re-
cruitment, cap methylation, and translation of a subset of
genes. Myc can be recruited to transcription initiation sites via
the N terminus alone. Myc can also bind CDK7 and promote
TFIIH recruitment in an MBII-dependent manner and there-
fore may have a direct role in this process. The fact that Myc
can significantly increase the level of CTD phosphorylation in
the total pool of RNA Pol II, rather than at specific promoters,
is evidence of the potent effect of the Myc N terminus. RNA
Pol II phosphorylation governs many aspects of transcription
and cotranscriptional processing (5, 29, 52), and the finding
that Myc can substantially increase CTD phosphorylation is
suggestive of a global role for Myc in these processes.
It is interesting that Myc can directly enhance the recruit-
ment of TFIIH to both the cyclin H and cyclin T1 promoters
(Fig. 7). Myc induces posttranscriptional elevation in these
cyclin protein levels as well as other CDK components. The
increased levels of these CDK/cyclin complexes could syner-
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FIG. 7. Myc promotes TFIIH binding and binds to the transcription initiation sites via the N terminus. ChIP was performed on myc/ fibroblasts
expressing MycWT, MycBM, MycC, or the vector control. (A) Complexes were immunoprecipitated with antibodies raised against the TFIIH subunits
MAT1 and p62 or control antibody. Coprecipitated DNA was used as a template for PCR using primers specific for cyclin T1, cyclin H, nucleolin
(NUCL), and GAPDH transcriptional start sites. PCR products were labeled, run on a gel, and visualized by a phosphorimager (upper panels). PCR
products were quantitated and normalized to input PCR, and the relative (Rel.) signal is depicted. The mean values for at least two independent
experiments are shown in the graphs. Error bars show the standard deviations. (B) Complexes were immunoprecipitated with anti-FLAG (Myc) or
control antibody. PCR was carried out using primers specific for HSP60 and nucleolin E boxes. (C) Complexes were immunoprecipitated with antibodies
raised against the FLAG (Myc) tag and Myc or control antibody. PCR was carried out using primers specific for cyclin T1, cyclin H, nucleolin, and
GAPDH transcription start sites. (D) 293 cells were transfected with MycWT, MycMBII, and CDK7 as indicated. Immunoprecipitation was carried out
with cell extracts using anti-CDK7 (left panel) or anti-Myc (middle panel). Immunoprecipitated proteins and cell extracts (right panel) were subjected
to Western blotting using anti-CDK7 and anti-Myc antibodies. (E) Immunoprecipitation was carried out using anti-c-Myc antibodies or control antibodies
on untransfected 293 cells. Immunoprecipitated protein and cell extracts were subjected to Western blotting using anti-CDK7 and anti-Myc antibodies.
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gize with Myc-induced recruitment in a positive feedback loop
to further enhance cellular CTD kinase levels.
Myc activates CAK and promotes proliferation indepen-
dently of target gene expression. Myc-driven cell proliferation
is essential for its role in development, normal cell physiology,
and cell transformation (8, 41). One of the most surprising
findings of this study is that the N terminus of Myc has suffi-
cient biological activity to actually rescue a large fraction of the
proliferation defect of myc null fibroblasts. Although MycC
and MycBM do not regulate the transcription of Myc target
genes, they have sufficient activity to rescue the cell doubling
time from 40 h to 26 h. MycC and MycBM were used as
complementary mutants since MycC cannot bind to Max,
whereas MycBM can. Since both mutants have an increased
proliferation rate, we can rule out disturbance of the Max
network as being responsible for this Myc N-terminal activity.
In addition, the N-terminal MycBMMBII mutant cannot in-
duce cell proliferation despite being able to bind to Max equiv-
alently to MycBM, thus localizing the proliferative activity to a
critical N-terminal domain.
Cell proliferation is driven by a cycle of CDK activation and
degradation. CAK phosphorylates other CDKs, increasing the
activity and stability of cell cycle CDK/cyclin complexes (23).
Previously, MycWT has been shown to increase cellular CAK
activity (32). In this paper, we show that MycWT and DNA
binding mutants increase the expression and activity of CAK
independently of target gene expression. In addition, we show
that CDK7 is rate limiting for CDK phosphorylation and cell
proliferation. Since CAK is also a component of TFIIH, it is
not possible to deduce whether inhibition of CDK7 reduces
cell proliferation because it inhibits TFIIH-induced RNA Pol
II phosphorylation or CAK-induced CDK phosphorylation.
Indeed, Myc may induce proliferation via CDK7 by activating
both TFIIH and CAK.
FIG. 7—Continued.
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A previous report which addressed the mechanism by which
Myc drives proliferation demonstrated that DNA binding and
dimerization with Max are necessary for Myc to maintain cells
in S phase following serum withdrawal (2), and indeed, our
non-DNA binding mutants behave similarly under serum-
starved conditions (unpublished data). We do not believe that
this previous study conflicts with our own because our studies
used log-phase cells, i.e., subconfluent cultures grown in serum.
These two studies reveal redundant mechanisms by which Myc
can drive proliferation, both dependent and independent of
gene regulation.
Myc regulation of mRNA cap methylation. In this paper, we
report the first example of the regulation of mammalian
mRNA cap methylation. Yeast mutant analysis and biochem-
ical assays have demonstrated that mRNA guanylylation is
necessary for stabilizing mRNA, and methylation of the gua-
nylyl group is necessary to permit translation of the mRNA
(40, 50, 51). Since these two steps are carried out by separate
enzymes and the addition of guanylyl and methyl groups occurs
with a time delay in vitro, it has been proposed that differential
regulation of these enzymes may exist (38, 51). Here, we show
that Myc can increase the methylation of specific messages and
that this is a property of the Myc N terminus alone. Myc is
recruited to transcription initiation sites accompanied by
TFIIH in an MBII-dependent manner. The TFIIH-phosphor-
ylated CTD has been reported to recruit methyltransferase,
but it remains possible that Myc may stimulate the methyl-
transferase either via TFIIH or more directly. It is interesting
to draw comparisons between our study of Myc and a recent
study of GAL4 (39). A GAL4 mutant was demonstrated to
increase CTD phosphorylation and translation rather than
transcription of target genes, and we propose that methylation
of these target gene mRNAs may be responsible for the in-
creased GAL4 target translation rate.
TFIIH recruitment is also associated with increased tran-
scription and mRNA guanylylation, both of which result in
increased mRNA abundance. However, in our system, al-
though we see Myc-dependent recruitment of TFIIH to some
promoters, we do not see an increase in mRNA abundance for
these genes. There are many explanations that could account
for this observation, the simplest being that transcription, cap-
ping, and cap methylation may be promoter dependent and
differentially sensitive to the TFIIH-phosphorylated CTD.
MycWT upregulates the transcription and translation of a
subset of Myc target genes. We found that two traditional Myc
target genes, the nucleolin and RUVBL1 genes, had increased
cap methylation and polysome loading in response to MycWT
and the DNA binding mutants. Consistent with increased poly-
some loading, we found that nucleolin and RUVBL1 protein
expression levels are also elevated in response to the expres-
sion of MycWT, MycBM, and MycC. The increase in protein
expression is larger in response to MycWT than to the DNA
binding mutants, consistent with these genes having both in-
creased transcription and increased translation in response to
MycWT. Thus, Myc may increase the protein concentration of
a large subset of genes by upregulating both their transcription
and their translation. Another Myc target gene, the HSP60
gene, did not exhibit a robust increase in cap methylation and
polysome loading in response to the Myc DNA binding mu-
tants, revealing that the recruitment of Myc to an E box is not
sufficient to stimulate cap methylation. A small increase in
HSP60 polysome loading was observed in response to MycWT,
and this may be a reflection of the increased expression of
eukaryotic initiation factors 4E and 4G induced by MycWT
(but not Myc DNA binding mutants) (47). Indeed, MycWT
expression has been reported previously to increase the poly-
some loading of specific mRNAs (36). More global studies will
be required to determine which target genes are cap methyl-
ated in response to Myc.
Summary. Myc is a potent and pleiotropic effector of cellu-
lar growth and a well-established transcription factor. Here, we
report that Myc activity extends beyond transcriptional regu-
lation of target genes to a general role in promoting global
phosphorylation of the RNA Pol II CTD. This activity is likely
to have broad-ranging effects on transcription and mRNA me-
tabolism, such as increased cap methylation on some mRNAs.
The combination of this global activity with the transactivation
of numerous target genes may account for the prominent role
of Myc as an oncogene.
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